0001213900-20-013773.txt : 20200601 0001213900-20-013773.hdr.sgml : 20200601 20200601083122 ACCESSION NUMBER: 0001213900-20-013773 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20200529 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200601 DATE AS OF CHANGE: 20200601 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OptimizeRx Corp CENTRAL INDEX KEY: 0001448431 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 261265381 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38543 FILM NUMBER: 20931074 BUSINESS ADDRESS: STREET 1: 400 WATER ST., STE. 200 CITY: ROCHESTER STATE: MI ZIP: 48307 BUSINESS PHONE: 248-651-6558 MAIL ADDRESS: STREET 1: 400 WATER ST., STE. 200 CITY: ROCHESTER STATE: MI ZIP: 48307 8-K 1 ea122522-8k_optimizerx.htm CURRENT REPORT

 

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): May 29, 2020

 

OptimizeRx Corporation

(Exact name of registrant as specified in its charter)

 

Nevada   001-38543   26-1265381
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (I.R.S. Employer
Identification No.)

 

400 Water Street, Suite 200, Rochester, MI   48307
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: 248.651.6568

 

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol   Name of each exchange on which registered
Common Stock   OPRX   Nasdaq Capital Market

 

 

 

 

 

 

SECTION 8 – Other Events

 

Item 8.01 Other Events

 

On May 29, 2020, we issued a press release concerning our invitation to present in William Blair & Company’s 40th Annual Growth Stock Conference being held June 9-11, 2020. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in Item 8.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

SECTION 9 – Financial Statements and Exhibits

 

Item 9.01 Financial Statements and Exhibits

 

99.1Press release, dated May 29, 2020

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

OptimizeRx Corporation  
   
/s/ Douglas Baker  
Douglas Baker  
Chief Financial Officer  
   
Date June 1, 2020  

 

 

2

 

EX-99.1 2 ea122522ex99-1_optimizerx.htm PRESS RELEASE, DATED MAY 29, 2020

Exhibit 99.1

 

 

 

OptimizeRx to Present at William Blair & Company’s 40th Annual Growth Stock Conference, June 9-11, 2020

 

ROCHESTER, Mich., (May 29, 2020) — OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, payers and providers, has been invited to present in William Blair & Company’s 40th Annual Growth Stock Conference being held June 9-11, 2020.

 

OptimizeRx CEO William Febbo is scheduled to present on June 10, 2020, at 9:20 a.m. Central time, as well as participate in virtual one-on-one meetings on the same day and June 11.

 

He will discuss a number of topics, including how OptimizeRx’s record Q1 results demonstrated an acceleration in platform adoption and the further transformation of the company’s revenue model into SaaS-based enterprise-level deployments. He will also discuss how COVID-19 has made OptimizeRx’s nationwide digital connectivity at the point-of-care even more relevant to its customer base, which now includes the world’s top 20 pharmaceutical companies.

 

The live presentation will be available at investors.optimizerx.com/events-and-presentations.

 

The event is for institutional clients of William Blair and is by invitation only. To schedule a one-on-one meeting with OptimizeRx, please contact your William Blair institutional sales representative. For further assistance or any questions about OptimizeRx, contact Ron Both of CMA at (949) 432-7557 or submit your inquiry here.

 

About William Blair

William Blair is a premier global boutique with expertise in investment banking, investment management, and private wealth management. The company provides advisory services, strategies, and solutions to meet its clients’ evolving needs. As an independent and employee-owned firm, together with its strategic partners, William Blair operates in more than 20 offices worldwide. For more information, visit www.williamblair.com.

 

About OptimizeRx®

OptimizeRx Corporation (NASDAQ: OPRX) is a digital health company that facilitates communication at point-of-care among all stakeholders in healthcare. Primarily focused on life science and payer clients, its suite of digital and mobile SaaS-based solutions enables affordability, patient adherence and care management. OptimizeRx’s network reaches more than 60% of U.S. ambulatory providers, delivering therapeutic support on specialty medications and patient financial assistance directly within a provider’s workflow through leading electronic health platforms. OptimizeRx’s fully integrated platform supports the real-time exchange of information, improving provider knowledge and patient engagement, and ultimately leading to healthier outcomes.

 

For more information, go to OptimizeRx.com, and follow the company on Twitter and LinkedIn.

 

Important Cautions Regarding Forward Looking Statements

This press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended, and such as in section 21E of the Securities Act of 1934, as amended. These forward-looking statements should not be used to make an investment decision. The words ‘estimate,’ ‘possible’ and ‘seeking’ and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, and other material risks.

 

OptimizeRx Contact

Doug Baker, CFO

Tel (248) 651-6568 x807

dbaker@optimizerx.com

 

Media Relations Contact

Maira Alejandra, Media Relations Manager

Tel (754) 245-7070

malejandra@optimizerx.com

 

Investor Relations Contact

Ron Both or Grant Stude

CMA Investor Relations

Tel (949) 432-7557

oprx@cma.team

GRAPHIC 3 eximg_001.jpg GRAPHIC begin 644 eximg_001.jpg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end